Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
about
The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapyA phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancerMulticenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer.Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancerA phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patientsRetrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer.A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.Complications associated with postoperative adjuvant radiation therapy for advanced rectal cancer.XELOX in colorectal cancer: a convenient option for the future?Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.[Palliative surgery in visceral medicine. Exemplified by colorectal and gastric cancer].Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer.A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
P2860
Q33739235-3C66FF70-1B5B-402F-940A-D8A8B9DD0876Q35194602-A7DFDA11-AE20-4871-B648-FF51C25C866FQ35807573-3F1210AB-4D22-4FA6-82C2-F6977324898CQ35819857-D743E30F-E47C-4A0E-9409-794AF2450D36Q36778075-542C71EE-A7D1-4B8C-B4FF-6ECEFA7D6DE9Q36813649-82A26CB4-4103-4E5A-BF1C-2CA7FA07AD0AQ37094989-BFD5E867-CBAE-4432-A3C2-C659291B3D82Q37272489-E39E4F4F-1431-4030-A551-8087388767D8Q37560960-FA58437B-8A40-4849-A9C8-E9FEBAFB423FQ37601319-154B3F53-24EB-4D5E-9488-69C93458EFABQ37660518-260F2DEF-8ADE-4EFA-A993-F124112EFD6CQ37670877-4E8581AE-4787-482C-AF33-ED1FE00BE5BAQ37839084-265A8245-A72D-46B1-8E5D-BA79128101E4Q38016098-30723749-49F9-40D0-9656-D5DCBB9ACC0BQ38551668-A02B5706-A64D-4F00-8757-1C32ABA60023Q38616424-0F77C92F-BA20-4075-8378-A85482EF44B9Q40922028-F5845DE2-0FDB-4BC9-846E-3E47C0018777Q41231221-7EC8D0FD-8BEC-4050-8AEF-9E606C12B0FCQ43409525-995532D4-C755-4011-8D6A-0C1C41344E0FQ47769444-685FE315-4F9E-42E1-9ADE-02F392D91D1BQ54577684-625B6EC7-4C5F-4D3A-9D44-B3292EFF63BAQ57131403-4BC60F59-CCBB-4A84-A89E-1D251764AF7C
P2860
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@ast
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@en
Phase I/II study of capecitabine plus oxaliplatin
@nl
type
label
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@ast
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@en
Phase I/II study of capecitabine plus oxaliplatin
@nl
prefLabel
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@ast
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@en
Phase I/II study of capecitabine plus oxaliplatin
@nl
P2093
P2860
P356
P1476
Phase I/II study of capecitabi ...... metastatic colorectal cancer.
@en
P2093
Atsushi Sato
Hiroya Takiuchi
Kensei Yamaguchi
Narikazu Boku
Nobuyuki Mizunuma
Wasaburo Koizumi
Yasuo Hamamoto
Yoshito Komatsu
P2860
P304
P356
10.1093/JJCO/HYQ069
P577
2010-05-12T00:00:00Z